Kraig Biocraft Laboratories, Inc 10-Q for FY2024 Q3

Kraig Biocraft Laboratories, Inc. (KBLB)

10-Q 2024-11-13 For: 2024-09-30

Added on April 05, 2026

About this 10-Q

Kraig Biocraft Laboratories, Inc filed this 10-Q on November 13, 2024, covering the quarter ended September 30, 2024 (FY2024 Q3).

Headline figures

Quarter ended September 30, 2024, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss: $433.2K; compared with a net loss of $549.27K a year earlier
Diluted EPS: $0.00; compared with $0.00 a year earlier

Search and read filings like this one from Claude or ChatGPT with the SEC filings MCP server →

Title of each class		Trading Symbol(s)		Name of exchange on which registered
None		-		-

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒	Smaller reporting company ☒
	Emerging growth company ☐

	Page

PART I FINANCIAL INFORMATION

Item 1. Unaudited Condensed Financial Statements:

Condensed Consolidated Balance Sheets as of September 30, 2024 (Unaudited) and December 31, 2023 (Audited)	3

Condensed Consolidated Statements of Operations (Unaudited) for the three and nine months ended September 30, 2024, and 2023	4

Condensed Consolidated Statement of Changes in Stockholders’ Deficit for the three and nine months ended September 30, 2024 (Unaudited)	5

Condensed Consolidated Statement of Changes in Stockholders’ Deficit for the three and nine months ended September 30, 2023 (Unaudited)	6

Condensed Consolidated Statements of Cash Flows (Unaudited) for the nine months ended September 30, 2024	7

Notes to Condensed Consolidated Financial Statements (Unaudited)	8

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	25

Item 3. Quantitative and Qualitative Disclosures about Market Risk	32

Item 4. Controls and Procedures	32

PART II OTHER INFORMATION

Item 1. Legal proceedings	33

Item 1A. Risk Factors	33

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	33

Item 3. Defaults upon Senior Securities	33

Item 4. Mine Safety Disclosures	33

Item 5. Other information	33

Item 6. Exhibits	34

	September 30, 2024			December 31, 2023
	(Unaudited)
ASSETS
Current Assets
Cash and cash equivalents	$	1,190,027		$	2,551,834
Inventory		6,884			6,884
Prepaid expenses		41,229			14,902
Total Current Assets		1,238,140			2,573,620

Property and Equipment, net		46,533			66,640
Investment in gold bullions (cost $450,216 and $450,216, respectively)		635,845			493,236
Operating lease right-of-use asset, net		98,666			95,808
Security deposit		7,174			3,518

Total Assets	$	2,026,358		$	3,232,822

LIABILITIES AND STOCKHOLDERS’ DEFICIT

Current Liabilities
Accounts payable and accrued expenses	$	514,449		$	541,637
Note payable - related party		1,617,000			1,617,000
Royalty agreement payable - related party		65,292			65,292
Accounts payable and accrued expenses - related party		7,086,560			6,584,648
Accounts payable and accrued expenses		7,086,560			6,584,648
Operating lease liability, current		57,518			41,789
Loan payable		-			35,244
Total Current Liabilities		9,340,819			8,885,610

Long Term Liabilities
Operating lease liability, net of current		42,548			54,368
Total Liabilities		9,383,367			8,939,978

Commitments and Contingencies (Note 9)		-			-

Stockholders’ Deficit
Preferred stock, no par value; unlimited shares authorized, none, issued and outstanding		-			-
Preferred stock Series A, no par value; 3 and 2 shares issued and outstanding, respectively		5,237,800			5,217,800
Preferred stock value		5,237,800			5,217,800
Common stock Class A, no par value; unlimited shares authorized, 1,038,374,219 and 1,030,940,008 shares issued and outstanding, respectively		27,385,611			27,385,611
Common stock Class B, no par value; unlimited shares authorized, no shares issued and outstanding		-			-
Common stock value		-			-
Common Stock Issuable, 1,122,311 and 1,122,311 shares, respectively		22,000			22,000
Additional paid-in capital		12,231,624			11,354,213
Accumulated Deficit		(52,234,044	)		(49,686,780	)

Total Stockholders’ Deficit		(7,357,009	)		(5,707,156	)

Total Liabilities and Stockholders’ Deficit	$	2,026,358		$	3,232,822


	For the Three Months Ended						For the Nine Months Ended
	September 30, 2024			September 30, 2023			September 30, 2024			September 30, 2023

Revenue	$	-		$	-		$	-		$	-

Operating Expenses
General and Administrative		205,298			224,687			1,467,411			656,457
Professional Fees		40,922			23,294			221,302			89,390
Officer’s Salary		152,609			172,335			566,115			515,584
Research and Development		24,968			39,129			103,817			165,256
Total Operating Expenses		423,797			459,445			2,358,645			1,426,687

Loss from Operations		(423,797	)		(459,445	)		(2,358,645	)		(1,426,687	)

Other Income/(Expenses)
Net change in unrealized depreciation on investment in gold bullion		78,420			(17,055	)		142,609			4,526
Interest expense		(132,890	)		(121,969	)		(393,713	)		(359,088	)
Amortization of debt issue costs		-			-			-			-
Gain on Asset Impairment		30,084						-			-
Interest income		14,983			49,196			62,485			76,103
Total Other Income/(Expenses)		(9,403	)		(89,828	)		(188,619	)		(278,459	)

Net (Loss) before Provision for Income Taxes		(433,200	)		(549,273	)		(2,547,264	)		(1,705,146	)

Provision for Income Taxes		-			-			-			-

Net (Loss)	$	(433,200	)	$	(549,273	)	$	(2,547,264	)	$	(1,705,146	)

Other Comprehensive Income
Change in unrealized value of available-for-sale securities, net of income tax	$	-		$	(13,021	)	$	-		$	-
Other Comprehensive Income

Total Operating and Comprehensive Loss	$	(433,200	)	$	(562,294	)	$	(2,547,264	)	$	(1,705,146	)

Net Income (Loss) Per Share - Basic and Diluted	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)

Weighted average number of shares outstanding during the period - Basic and Diluted		1,038,374,219			1,033,374,219			1,038,374,219			1,032,946,226

	Shares		Par		Shares		Par		Shares		Par		Shares		Par		APIC		-	Deficit			Total
	Preferred Stock - Series A				Common Stock - Class A				Common Stock - Class B				To be issued							Accumulated
	Shares		Par		Shares		Par		Shares		Par		Shares		Par		APIC			Deficit			Total

Balance, June 30, 2024(Unaudited		3	$	5,237,800		1,038,374,219	$	27,385,611		-	$	-		1,122,311	$	22,000	$	12,183,754	-	$	(51,800,844	)		(6,971,679	)

Warrants issued for services - related parties		-		-		-		-		-		-		-		-		13,500			-			13,500

Warrants issued for services		-		-		-		-		-		-		-		-		13,991			-			13,991

Imputed interest - related party		-		-		-		-		-		-		-		-		20,379			-			20,379

Net loss for the three months ended September 30, 2024		-		-		-		-		-		-		-		-		-	-		(433,200	)		(433,200	)

Balance, September 30, 2024 (Unaudited)		3	$	5,237,800		1,038,374,219	$	27,385,611		-	$	-		1,122,311	$	22,000	$	12,231,624	-	$	(52,234,044	)		(7,357,009	)

Balance, December 31, 2023 (Audited)		2	$	5,217,800		1,038,374,219	$	27,385,611		-	$	-		1,122,311	$	22,000	$	11,354,213	-	$	(49,686,780	)		(5,707,156	)

Preferred share issued in connection with debt cancellation - related party		1		20,000		-		-		-		-		-		-		-			-			20,000

Warrants issued for services - related parties		-		-		-		-		-		-		-		-		761,169			-			761,169

Warrants issued for services		-		-		-		-		-		-		-		-		55,549			-			55,549

Imputed interest - related party		-		-		-		-		-		-		-		-		60,693			-			60,693

Net loss for the nine months ended September 30, 2024		-		-		-		-		-		-		-		-		-	-		(2,547,264	)		(2,547,264	)

Balance, September 30, 2024 (Unaudited)		3	$	5,237,800		1,038,374,219	$	27,385,611		-	$	-		1,122,311	$	22,000	$	12,231,624	-	$	(52,234,044	)		(7,357,009	)

	2024			2023
	For the Nine Months Ended September 30,
	2024			2023
Cash Flows From Operating Activities:
Net Loss	$	(2,547,264	)	$	(1,705,146	)
Adjustments to reconcile net loss to net cash used in operations
Depreciation expense		20,107			20,042
Net change in unrealized appreciation and depreciation in gold bullions		(142,609	)		(4,526	)
Change in fair value of marketable securities		-			-
Imputed interest - related party		60,693			60,472
Warrants issued/(cancelled) to consultants		816,718			168,001
Changes in operating assets and liabilities:
(Increase) Decrease prepaid expenses		(26,327	)		15,503
(Increase) in Deposits		(3,656	)		-
Decrease in operating lease right-of-use, net		36,631			36,428
Increase in accrued expenses and other payables - related party		521,912			550,626
Decrease in accounts payable		(27,188	)		(20,686	)
Decrease in operating lease liabilities, current		(35,580	)		(37,476	)
Net Cash Used In Operating Activities		(1,326,563	)		(916,762	)

Net Cash Used In Investing Activities
Purchase of treasury bills		-			(2,587,811	)
Proceeds from maturity of treasury bills		-			2,587,811
Purchase of fixed assets		-			(6,399	)
Net Cash Provided by Investing Activities		-			(6,399	)

Cash Flows From Financing Activities:
Principal payments on debt		(35,244	)		(45,000	)
Net Cash Provided by Financing Activities		(35,244	)		(45,000	)

Net Change in Cash and Cash Equivalents		(1,361,807	)		(968,161	)

Cash and Cash Equivalents at Beginning of Period		2,551,834			3,862,716

Cash and Cash Equivalents at End of Period	$	1,190,027		$	2,894,555

Supplemental disclosure of cash flow information:

Cash paid for interest	$	-		$	-
Cash paid for taxes	$	-		$	-

Supplemental disclosure of non-cash investing and financing activities:
Shares issued in connection with cashless warrants exercise	$	-		$	100,000
Adoption of lease standard ASC 842	$	30,084		$	85,023
Adoption of lease standard ASC 842	$	39,489		$	-
Preferred share issued in connection with debt cancellation - related party	$	20,000		$	-

	September 30, 2024		December 31, 2023

Stock Warrants (Exercise price - $0.001- $0.25/share)		81,035,714		67,335,714
Stock Options (Exercise price - $0.1150/Share)		26,520,000		26,520,000
Convertible Preferred Stock		3		2
Total		107,555,717		93,855,716

	●	Level 1 - Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access. We believe our carrying value of level 1 instruments approximate their fair value at September 30, 2024, and 2023.

	●	Level 2 - Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.

	●	Level 3 - Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. We consider depleting assets, asset retirement obligations and net profit interest liability to be Level 3. We determine the fair value of Level 3 assets and liabilities utilizing various inputs, including NYMEX price quotations and contract terms.

	September 30, 2024								December 31, 2023
	Fair Value Measurement Using								Fair Value Measurement Using
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total

Assets:
Investment in gold	$	635,845	$	-	$	-	$	635,845	$	493,236	$	-	$	-	$	493,236
Money market fund	$	1,094,971	$	-	$	-	$	1,094,971	$	2,409,486	$	-	$	-	$	2,409,486
Total	$	1,730,816	$	-	$	-	$	1,730,816	$	2,902,722	$	-	$	-	$	2,902,722

Nine Months Ended September 30, 2024	Ounces		Cost		Fair Value

Balance December 31, 2023		239	$	2,064	$	493,236
Net change in unrealized gain		-		268		142,609
Balance September 30, 2024		239	$	2,332	$	635,845

	September 30, 2024			December 31, 2023			Estimated Useful Lives (Years)
Automobile	$	41,805		$	41,805			5
Laboratory Equipment		130,310			130,310			5-10
Office Equipment		7,260			7,260			5-10
Leasehold Improvements		82,739			82,739			2-5
Property and Equipment, gross		82,739			82,739

Less: Accumulated Depreciation		(215,581	)		(195,474	)
Total Property and Equipment, net	$	46,533		$	66,640

Lease Term		Annual Rent
9/20/2024	9/30/2026	$	7,200.00
10/1/2026	12/31/2027	$	7,920.00
1/1/2028	12/31/2030	$	8,712.00


2024 (3 Months)	$	15,861
2025		51,544
2026		13,143
2027		7,920
2028		26,137
Total lease payments		114,605
Less: amount representing interest		(14,539	)
Total lease obligations		100,066
Total lease payments		114,605

Less: current portion of operating lease liability		(57,518	)
Long-term portion operating lease liability	$	42,548

1.	$5,000 per month for months one through thirteen.
2.	Final payment of the remaining balance in the amount of $115,244 split into two equal payments, of which $57,622 to be paid in month fourteen and $57,622 paid in month twenty.

Expected dividends	0	%
Expected volatility	133.80	%
Expected term	7 years
Risk free interest rate	3.76	%
Expected forfeitures	0	%

Expected dividends	0	%
Expected volatility	134.80	%
Expected term	4.25 -4.75 4.25 years
Risk free interest rate	4.54	%
Expected forfeitures	0	%

Expected dividends	0	%
Expected volatility	130.50	%
Expected term	4.75 years
Risk free interest rate	4.54	%
Expected forfeitures	0	%

Expected dividends	0	%
Expected volatility	138.60	%
Expected term	3.25 years
Risk free interest rate	4.60	%
Expected forfeitures	0	%

Expected dividends	0	%
Expected volatility	138.30	%
Expected term	3.25 years
Risk free interest rate	4.48	%
Expected forfeitures	0	%

Expected dividends	0	%
Expected volatility	133.30	%
Expected term	6.25 years
Risk free interest rate	4.04	%
Expected forfeitures	0	%

Expected dividends	0	%
Expected volatility	133.22	%
Expected term	7 years
Risk free interest rate	1.46	%
Expected forfeitures	0	%

Expected dividends	0	%
Expected volatility	125.19	%
Expected term	3 years
Risk free interest rate	1.50	%
Expected forfeitures	0	%

Warrants	Number of Warrants			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Outstanding – December 31, 2023		67,335,714		$	0.12		3.89	$	331,500
Exercisable – December 31, 2023		67,335,714		$	0.12		3.89	$	331,500

Granted		16,700,000		$	0.0895		7.78		49,920
Exercised		-		$	-		-		-
Cancelled/Forfeited		(3,000,000	)	$	0.2299		-		-
Outstanding – September 30, 2024		81,035,714		$	0.0895		4.57	$	1,853,660
Exercisable – September 30, 2024		81,035,714		$	0.10		4.57	$	1,853,660

Exercise Price Warrants Outstanding		Warrants Exercisable		Weighted Average Remaining Contractual Life		Aggregate Intrinsic Value
$	0.001		8,500,000		1.39	$	729,300
$	0.04		2,300,000		2.00	$	107,640
$	0.056		1,000,000		0.77	$	30,800
$	0.2299		4,125,000		1.34	$	-
$	0.16		3,125,000		1.20	$	-
$	0.25		8,000,000		1.48	$	-
$	0.1160		500,000		0.77	$	-
$	0.12		12,500,000		2.29	$	-
$	0.14		4,285,714		2.29	$	-
$	0.04		4,000,000		8.21	$	187,200
$	0.04		6,000,000		8.21	$	280,800
$	0.04		10,000,000		8.21	$	468,000
$	0.0825		5,000,000		8.03	$	22,750
$	0.0825		5,000,000		8.87	$	22,750
$	0.08		150,000		6.01	$	1,020
$	0.08		500,000		6.01	$	3,400
$	0.1024		2,000,000		6.86	$	-
$	0.1024		2,000,000		6.86	$	-
$	0.1024		2,000,000		6.86	$	-
$	0.1024		50,000		6.86	$	-
			81,035,714			$	1,853,660

Options	Number of Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Outstanding - December 31, 2023		26,520,000	$	0.12		17.27	$	-
Granted		-	$	-		-		-
Exercised		-	$	-		-		-
Cancelled/Forfeited		-	$	-		-		-
Outstanding – September 30, 2024		26,520,000	$	0.12		16.51	$	-
Exercisable – September 30, 2024		26,520,000	$	0.12		16.51	$	-

●	Common stock Class A, unlimited number of shares authorized, no par value
●	Common stock Class B, unlimited number of shares authorized, no par value
●	Preferred stock, unlimited number of shares authorized, no par value

	As of September 30, 2024		As of December 31, 2023

Accounts payable - related party	$	294,281	$	388,001
Accrued expenses - related party		3,779,023		3,516,411
Accrued interest - related party		3,013,256		2,680,236
Total accounts payable and accrued expenses - related party	$	7,086,560	$	6,584,648

●	We plan to develop a line of fabrics and apparel, to create a line of spider silk based fashion and performance wear. The company plans to pursue this market entry in combination with one or more joint venture or development partners.

●	We plan to continue the expansion of our spider silk production capacity including new facilities and expansion of existing facilities.

●	We plan to continue and accelerate our work to improve the overall robustness of our recombinant spider silk lines through a combination of climate acclimation, improved silkworm genetics, and the implementation of a multiple-strain hybrid breeding program. This program is already in an advanced state

●	We plan to accelerate both our microbiology and selective breeding programs, as well as provide more resources for our material testing protocols. We spent approximately $79,000 over the last 6 months on research and development of high strength polymers. In 2024, we are directing our research and development efforts on growing our internal capabilities.

●	We will consider buying an established revenue producing company in a compatible business, in order to broaden our financial base and facilitate the commercialization of our products; as of the date hereof, we have not had any formal discussion or entered into any definitive agreements regarding any such purchase.
●	We will also actively consider pursuing collaborative research opportunities with private laboratories in areas of research that overlap the company’s existing research and development. One such potential area for collaborative research that the company is considering is protein expression platforms. If our financing allows, management will strongly consider increasing the breadth of our research to include protein expression platform technologies.

●	We plan to actively pursue collaborative research and product testing opportunities with companies in the biotechnology, materials, textile and other industries.

●	We plan to actively pursue additional collaborative commercialization, marketing and manufacturing opportunities with companies in the textile and material sectors for the fibers we developed and for any new polymers that we create in 2024 and going forward.

●	We plan to actively pursue the development of commercial scale production of our recombinant materials including under the brand names: Monster Silk®, Dragon Silk^TM, SpydaSilk^TM, and Spydra^TM.

	Three Months Ended September 30,									% Change Increase
	2024			2023			Change			(Decrease)
NET REVENUES	$	-		$	-			-			-
COSTS OF REVENUES		-			-			-
Gross Profit		-			-			-
OPERATING EXPENSES:
General and Administrative		205,298			224,687			(19,389	)		-8.63	%
Professional Fees		40,922			23,294			17,628			75.68	%
Officer’s Salary		152,609			172,335			(19,726	)		-11.45	%
Research and Development		24,968			39,129			(14,161	)		-36.19	%
Total operating expenses		423,797			459,445			(35,648	)		-7.76	%
Loss from operations		(423,797	)		(459,445	)		35,648			-7.76	%
Interest expense		(132,890	)		(121,969	)		(10,921	)		8.95	%
Gain on Asset Impairment		30,084			-			30,084			100.00	%
Net change in unrealized appreciation on investment in gold bullion		78,420			(17,055	)		95,475			-559.81	%
Interest income		14,983			49,196			(34,213	)		69.54	%
Net Loss	$	(433,200	)	$	(549,273	)		116,073			-21.13	%

	Nine Months Ended September 30,									% Change Increase
	2024			2023			Change			(Decrease)
NET REVENUES	$	-		$	-			-			-
COSTS OF REVENUES		-			-			-
Gross Profit		-			-			-
OPERATING EXPENSES:
General and Administrative		1,467,411			656,457			810,954			123.53	%
Professional Fees		221,302			89,390			131,912			147.57	%
Officer’s Salary		566,115			515,584			50,531			9.80	%
Research and Development		103,817			165,256			(61,439	)		-37.18	%
Total operating expenses		2,358,645			1,426,687			931,958			65.32	%
Loss from operations		(2,358,645	)		(1,426,687	)		(931,958	)		65.32	%
Interest expense		(393,713	)		(359,088	)		(34,625	)		9.64	%
Net change in unrealized appreciation on investment in gold bullion		142,609			4,526			138,083			3050.88	%
Interest income		62,485			76,103			(13,618	)		(17.89	)%
Net Loss	$	(2,547,264	)	$	(1,705,146	)		(842,118	)		49.39	%

	September 30, 2024		December 31, 2023
Cash	$	1,190,027	$	2,551,834
Inventory	$	6,884	$	6,884
Prepaid expenses	$	41,229	$	14,902
Total current assets	$	1,238,140	$	2,573,620
Total assets	$	2,026,358	$	3,232,822
Total current liabilities	$	9,340,819	$	8,885,610
Total liabilities	$	9,383,367	$	8,939,978

Exhibit No.		Description
3.1		Articles of Incorporation (1)
3.2		Articles of Amendment (2)
3.3		Articles of Amendment, filed with the Wyoming Secretary of State on November 15, 2013 (3)
3.4		Articles of Amendment, filed with the Wyoming Secretary of State on December 17, 2013 (4)
3.5		Bylaws (1)
4.1		Form of Warrant issued Mr. Jonathan R. Rice (5)
4.2		Form of Warrant issued pursuant to that certain Purchase Agreement dated as of March 8, 2019 (7)
4.3		Form of Convertible Debenture (8)
4.4		Form of Warrant (8)
4.5		Form of A&R Convertible Debenture (8)
10.1		Employment Agreement between Mr. Jonathan Rice and the Company (6)
10.2		Form of Purchase Agreement dated March 8, 2019 (7)
10.3		Form of Securities Purchase Agreement (8)
10.4		Form of Guaranty Agreement (8)
10.5		Form of Security Agreement (8)
10.6		Form of IP Security Agreement (8)
10.7		Form of Registration Rights Agreement (8)
10.8		Strategic Partnership Agreement (portions of the exhibit have been omitted because they (i) are not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed) (9)
10.9		Amendment (portions of the exhibit have been omitted because they (i) are not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed) (9)
31.1		Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)
31.2		Certification of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)
32.1		Certification of the Principal Executive Officer pursuant to U.S.C. Section 1350 As adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith)
32.2		Certification of the Principal Financial Officer pursuant to U.S.C. Section 1350 As adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith)
101.INS		Inline XBRL Instance Document (filed herewith)
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

1.	Incorporated by reference to our Registration Statement on Form SB-2 (Reg. No. 333-146316) filed with the SEC on September 26, 2007.
2.	Incorporated by reference to our Registration Statement on Form S-1 (Reg. No. 333-162316) filed with the SEC on October 2, 2009.
3.	Incorporated by reference to our Current Report on Form 8-K filed with the SEC on November 22, 2013.
4.	Incorporated by reference to our Current Report on Form 8-K filed with the SEC on December 19, 2013.
5.	Incorporated by reference to our Annual Report on Form 10-K filed with the SEC on March 31, 2015.
6.	Incorporated by reference to our Current Report on Form 8-K filed with the SEC on January 21, 2015.
7.	Incorporated by reference to our Current Report on Form 8-K filed with the SEC on March 11, 2019.
8.	Incorporated by reference to our Current Report on Form 8-K filed with the SEC on March 26, 2021.
9.	Incorporated by reference to our Current Report on Form 8-K filed with the SEC on January 26, 2021.

	Kraig Biocraft Laboratories, Inc.
	(Registrant)

Date: November 13, 2024	By:	/s/ Kim Thompson
		Kim Thompson
		President, Chief Executive Officer and
		Chief Financial Officer (Principal Executive Officer and
		Principal Financial and Accounting Officer)